The BARDA contract includes pre-clinical efficacy and toxicology studies; clinical studies; manufacturing activities; and associated regulatory activities of TP-434.
The contract includes a 12-month base period with committed funding of $11.5m and subsequent option periods that, if completed, would bring the total value of the award to approximately $67m.
Tetraphase will work on this contract with CUBRC, the company said.
TP-434 as a potential empiric countermeasure for the treatment of inhalational disease caused by Bacillus anthracis, Francisella tularensis and Yersinia pestis.
Tetraphase president and CEO Guy Macdonald said BARDA’s award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase’s antibiotics to more than $100m.